RLD2203

DRUG3 trials

Sponsors

Hanmi Pharmaceutical Company Limited

Conditions

Healthy

Phase 1

A Study to Evaluate Pharmacokinetic/Pharmacodynamic Drug-drug Interaction and Safety/Tolerability Between RLD2202 and RLD2203

CompletedNCT05481307

Hanmi Pharmaceutical Company LimitedHealthy

Start: 2022-08-02End: 2022-10-25Updated: 2023-09-22

A Study to Evaluate the Pharmacokinetics and Safety Between HCP2202 and Co-administration of Each Component in Healthy Volunteers

CompletedNCT05548387

Hanmi Pharmaceutical Company LimitedHealthy

Start: 2022-09-02End: 2022-11-10Updated: 2023-09-22

A Study to Evaluate the Pharmacokinetics and Safety Between HCP2202 and Co-administration of Each Component in Healthy Volunteers Under Fed Conditions

CompletedNCT05548543

Hanmi Pharmaceutical Company LimitedHealthy

Start: 2022-10-17End: 2022-12-22Updated: 2023-09-22